Ipilimumab/nivolumab: Ventricular fibrillation and cardiac arrest.

Author InformationAn event is serious (based on the ICH definition) when the patient outcome is:• * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important eventA 65-year-old man developed ventricular fibrillation and cardiac arrest during treatment with nivolumab and ipilimumab for non-small cell lung cancer [dosages, routes and times to reactions onsets not stated]. [Extracted from the article]